CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$40.15−0.22 (-0.54%)
Close on Nov 17, 2026Market cap $3.88BP/E –Yield –
CRISPR Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
CRISPR Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -3368.7%. For fiscal 2025 it was -16569.8%, against -981.5% the year before. The highest annual figure on record is 41.3% in fiscal 2021.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -16569.8% | −15588.2 |
| FY2024 | Dec 31, 2024 | -981.5% | −940.2 |
| FY2023 | Dec 31, 2023 | -41.4% | +54230.3 |
| FY2022 | Dec 31, 2022 | -54271.7% | −54313.0 |
| FY2021 | Dec 31, 2021 | 41.3% | +48562.1 |
| FY2020 | Dec 31, 2020 | -48520.9% | −48543.9 |
| FY2019 | Dec 31, 2019 | 23.1% | +5304.2 |
| FY2018 | Dec 31, 2018 | -5281.1% | −5114.3 |
| FY2017 | Dec 31, 2017 | -166.7% | +282.1 |
| FY2016 | Dec 31, 2016 | -448.8% | +9876.3 |
| FY2015 | Dec 31, 2015 | -10325.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -895.3% | +22484.6 |
| Q1 FY2026 | Mar 31, 2026 | -8431.5% | +7290.6 |
| Q4 FY2025 | Dec 31, 2025 | -15117.2% | −15012.7 |
| Q3 FY2025 | Sep 30, 2025 | -11973.1% | +2303.0 |
| Q2 FY2025 | Jun 30, 2025 | -23379.9% | +1070.4 |
| Q1 FY2025 | Mar 31, 2025 | -15722.1% | +7411.1 |
| Q4 FY2024 | Dec 31, 2024 | -104.5% | −148.9 |
| Q3 FY2024 | Sep 30, 2024 | -14276.1% | −14165.0 |
| Q2 FY2024 | Jun 30, 2024 | -24450.3% | −24397.2 |
| Q1 FY2024 | Mar 31, 2024 | -23133.1% | +1819783.5 |
| Q4 FY2023 | Dec 31, 2023 | 44.4% | +185734.8 |
| Q2 FY2023 | Jun 30, 2023 | -111.1% | +117505.4 |
| Q1 FY2023 | Mar 31, 2023 | -53.1% | +19012.6 |
| Q4 FY2022 | Dec 31, 2022 | -1842916.7% | −1841821.6 |
| Q3 FY2022 | Sep 30, 2022 | -185690.4% | −170259.2 |
| Q2 FY2022 | Jun 30, 2022 | -117616.5% | −117700.7 |
| Q1 FY2022 | Mar 31, 2022 | -19065.6% | +1929.4 |
| Q4 FY2021 | Dec 31, 2021 | -1095.0% | +27834.4 |
| Q3 FY2021 | Sep 30, 2021 | -15431.2% | +47027.6 |
| Q2 FY2021 | Jun 30, 2021 | 84.3% | +181120.7 |
| Q1 FY2021 | Mar 31, 2021 | -20995.0% | +23419.7 |
| Q4 FY2020 | Dec 31, 2020 | -28929.5% | −28969.1 |
| Q3 FY2020 | Sep 30, 2020 | -62458.8% | −62524.1 |
| Q2 FY2020 | Jun 30, 2020 | -181036.4% | −164149.9 |
| Q1 FY2020 | Mar 31, 2020 | -44414.6% | −29656.1 |
| Q4 FY2019 | Dec 31, 2019 | 39.7% | +41422.3 |
| Q3 FY2019 | Sep 30, 2019 | 65.3% | +9072.6 |
| Q2 FY2019 | Jun 30, 2019 | -16886.5% | −13358.9 |
| Q1 FY2019 | Mar 31, 2019 | -14758.5% | −12674.6 |
| Q4 FY2018 | Dec 31, 2018 | -41382.6% | −41383.0 |
| Q3 FY2018 | Sep 30, 2018 | -9007.3% | −7972.2 |
| Q2 FY2018 | Jun 30, 2018 | -3527.6% | −2904.6 |
| Q1 FY2018 | Mar 31, 2018 | -2083.9% | −1289.5 |
| Q4 FY2017 | Dec 31, 2017 | 0.4% | −729.0 |
| Q3 FY2017 | Sep 30, 2017 | -1035.1% | −87.4 |
| Q2 FY2017 | Jun 30, 2017 | -623.0% | – |
| Q1 FY2017 | Mar 31, 2017 | -794.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 729.5% | – |
| Q3 FY2016 | Sep 30, 2016 | -947.7% | – |
See a number that looks wrong?